Skip to main page content
U.S. flag

An official website of the United States government

Dot gov

The .gov means it’s official.
Federal government websites often end in .gov or .mil. Before sharing sensitive information, make sure you’re on a federal government site.

Https

The site is secure.
The https:// ensures that you are connecting to the official website and that any information you provide is encrypted and transmitted securely.

Access keys NCBI Homepage MyNCBI Homepage Main Content Main Navigation

Search Page

Filters

My Custom Filters

Publication date

Text availability

Article attribute

Article type

Additional filters

Article Language

Species

Sex

Age

Other

Search Results

709 results

Filters applied: . Clear all
Results are displayed in a computed author sort order. The Publication Date timeline is not available.
Page 1
Lung mast cells are a source of secreted phospholipases A2.
Triggiani M, Giannattasio G, Calabrese C, Loffredo S, Granata F, Fiorello A, Santini M, Gelb MH, Marone G. Triggiani M, et al. Among authors: calabrese c. J Allergy Clin Immunol. 2009 Sep;124(3):558-65, 565.e1-3. doi: 10.1016/j.jaci.2009.04.035. Epub 2009 Jul 9. J Allergy Clin Immunol. 2009. PMID: 19541351 Free PMC article.
Metabolism of lipid mediators in human eosinophils.
Triggiani M, Calabrese C, Granata F, Gentile M, Marone G. Triggiani M, et al. Among authors: calabrese c. Chem Immunol. 2000;76:77-98. doi: 10.1159/000058779. Chem Immunol. 2000. PMID: 10761306 Review. No abstract available.
Features of severe asthma response to anti-IL5/IL5r therapies: identikit of clinical remission.
Carpagnano GE, Portacci A, Nolasco S, Detoraki A, Vatrella A, Calabrese C, Pelaia C, Montagnolo F, Scioscia G, Valenti G, D'Amato M, Caiaffa MF, Triggiani M, Scichilone N, Crimi C. Carpagnano GE, et al. Among authors: calabrese c. Front Immunol. 2024 Jan 23;15:1343362. doi: 10.3389/fimmu.2024.1343362. eCollection 2024. Front Immunol. 2024. PMID: 38327518 Free PMC article.
Long-Term Clinical and Sustained REMIssion in Severe Eosinophilic Asthma Treated With Mepolizumab: The REMI-M Study.
Crimi C, Nolasco S, Noto A, Maglio A, Quaranta VN, Di Bona D, Scioscia G, Papia F, Caiaffa MF, Calabrese C, D'Amato M, Pelaia C, Campisi R, Vitale C, Ciampo L, Dragonieri S, Minenna E, Massaro F, Gallotti L, Macchia L, Triggiani M, Scichilone N, Valenti G, Pelaia G, Foschino Barbaro MP, Carpagnano GE, Vatrella A, Crimi N; Southern Italy Network on Severe Asthma Therapy. Crimi C, et al. Among authors: calabrese c. J Allergy Clin Immunol Pract. 2024 Dec;12(12):3315-3327. doi: 10.1016/j.jaip.2024.08.033. Epub 2024 Aug 27. J Allergy Clin Immunol Pract. 2024. PMID: 39197750 Free article.
Cluster Analysis Identifies Patients With Severe Eosinophilic Asthma Who Achieve Super-Response and Remission With Mepolizumab.
Di Bona D, Bilancia M, Crimi C, Daddato M, Benfante A, Caiaffa MF, Calabrese C, Campisi R, Nolasco S, Carpagnano GE, D'Amato M, Pelaia C, Pelaia G, Maglio A, Scichilone N, Scioscia G, Spadaro G, Triggiani M, Carrieri I, Valenti G, Vatrella A, Macchia L, Crimi N. Di Bona D, et al. Among authors: calabrese c. Clin Exp Allergy. 2024 Oct 10. doi: 10.1111/cea.14584. Online ahead of print. Clin Exp Allergy. 2024. PMID: 39390847
709 results